Selective blockade of nicotinic acetylcholine receptors by pimobendan, a drug for the treatment of heart failure: Reduction of catecholamine secretion and synthesis in adrenal medullary cells

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 371, Issue 2, 2005, Pages 107-113

  Toyohira, Yumiko ^a   Kubo, Tatsuhiko ^a   Watanabe, Miyabi ^a   Uezono, Yasuhito ^b   Ueno, Susumu ^a   Shinkai, Koji ^a   Tsutsui, Masato ^a   Izumi, Futoshi ^a   Yanagihara, Nobuyuki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Adrenal medullary cells; Ca2+ influx; Catecholamine; Nicotinic acetylcholine receptors; Pimobendan; Secretion; Synthesis; Tyrosine hydroxylase

Indexed keywords

ALANINE; CALCIUM SENSITIZER; CARBACHOL; CARBON 14; CATECHOLAMINE; DOPA; DRUG METABOLITE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; O NORPIMOBENDAN; PIMOBENDAN; POTASSIUM ION; SODIUM CHANNEL STIMULATING AGENT; SODIUM ION; TYROSINE; VERATRIDINE;

ADRENAL MEDULLA; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CATECHOLAMINE RELEASE; CATECHOLAMINE SYNTHESIS; CHOLINERGIC RECEPTOR BLOCKING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; HEART FAILURE; IC 50; NONHUMAN; PHARMACOLOGICAL BLOCKING; POTASSIUM TRANSPORT; RECEPTOR UPREGULATION; SODIUM TRANSPORT;

ADRENAL MEDULLA; ANIMALS; CALCIUM; CARBACHOL; CARDIOTONIC AGENTS; CATECHOLAMINES; CATTLE; CELLS, CULTURED; DRUG INTERACTIONS; NICOTINIC ANTAGONISTS; PYRIDAZINES; SODIUM; VERATRIDINE;

EID: 16844362097     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-005-1020-3     Document Type: Article

References (24)

1. Böhm M, Morano I, Pieske B, Caspar R, Wankerl M, Zimmermann R, Erdmann E (1991) Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 68:689-701
2. Chu KM, Shieh SM, Hu OY (1995) Pharmacokinetics and pharmacodynamics enantiomers of pimobendan patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. Clin Pharmacol Ther 57:610-621
3. Colucci WS, Wright RF, Braunwald E (1986) New positive inotropic agents in the treatment of congestive heart failure. N Engl J Med 314:349-358
4. Costa V, Nistri A, Cavalli A, Carloni P (2003) A structural model of agonist binding to the α3β4 neuronal nicotinic receptor. Br J Pharmacol 140:921-931
5. Di Angelantonio S, Matteoni C, Fabbretti E, Nistri A (2003) Molecular biology and electrophysiology of neuronal nicotinic receptors of ratchromaffin cells. Eur J Neurosci 11:2313-2322
6. 1-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 113:1379-1382
7. Fujimoto S, Matsuda T (1990) Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats. J Pharmacol Exp Ther 252:1304-1311
8. Hagemeijer F (1993) Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J 14:551-566
9. Hagemeijer F, Brand HJ, Roth W (1989) Cardiovascular effects and plasma level profile of pimobendan (UD-CG115 BS) and its metabolite UD-CG212 in patients with congestive heart failure after single and repeated oral dosing. J Cardiovasc Pharmacol 14:302-310
10. Jaquet K, Heilmeyer LM Jr (1987) Influence of association and of positive inotropic drugs on calcium binding to cardiac troponin C. Biochem Biophys Res Commun 145:1390-1396
11. + channels in cultured bovine adrenal medullary cells. J Pharmacol Exp Ther 302:212-218
12. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD (1995) Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26:1257-1263
13. Kuwashima H, Matsumura C, Kimura T (2003) Inhibition and facilitation by pimobendan, a calcium sensitizer, of catecholamine secretion from bovine adrenal chromaffin cells. J Pharmacol Sci 91:211-218
14. Marley PD, Thomson KA, Bralow RA (1995) Protein kinase A and nicotinic activation of bovine adrenal tyrosine hydroxylase. Br J Pharmacol 114:1687-1693
15. Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR (2001) Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 92:89-108
16. Sasayama S (2002) Inotropic agents and immune modulation. Cardiovasc Drugs Ther 16:237-243
17. Sata M, Sugiura S, Yamashita H, Aoyagi T, Momomura S, Serizawa T (1995) Pimobendan directly reconstituted thin filament to slide on cardiac myosin. Eur J Pharmacol 290:55-59
18. +: determination of the sites on tyrosine hydroxylase phosphorylated by cyclic AMP-dependent and calcium/calmodulin-dependent protein kinases. Mol Pharmacol 30:476-485
19. Tsutsui M, Yanagihara N, Minami K, Kobayashi H, Nakashima Y, Kuroiwa A, Izumi F (1994) C-type natriuretic peptide stimulates catecholamine synthesis through the accumulation of cyclic GMP in cultured bovine adrenal medullary cells. J Pharmacol Exp Ther 268:584-589
20. Utsunomiya K, Yanagihara N, Tachikawa E, Cheah TB, Kajiwara K, Toyohira Y, Ueno S, Izumi F (2001) Stimulation of catecholamine synthesis in cultured bovine adrenal medullary cells by leptin. J Neurochem 76:926-934
21. 45Ca influx and secretion of catecholamines in cultured bovine adrenal medulla cells. Neuroscience 15:283-292
22. + removal. J Neurochem 49:1740-1746
23. Yanagihara N, Okazaki M, Terao T, Uezono Y, Wada A, Izumi F (1991) Stimulatory effects of brain natriuretic peptide on cyclic GMP accumulation and tyrosine hydroxylase activity in cultured bovine adrenal medullary cells. Naunyn-Schmiedeberg's Arch Pharmacol 343:289-295
24. 2+ in cultured bovine adrenal medullary cells. J Biol Chem 271:17463-17468